Cardiothoracic Division, The James Cook University Hospital, Middlesbrough, UK.
Cardiovasc Ther. 2012 Apr;30(2):e81-8. doi: 10.1111/j.1755-5922.2010.00239.x. Epub 2010 Nov 11.
Coronary artery disease is the single leading cause of death in the United States. Occlusion of the coronary artery was identified to be the cause of myocardial infarction almost a century ago. Following a series of investigations, streptokinase was discovered and demonstrated to be beneficial for the treatment of patients with acute myocardial infarction in terms of reducing short- and long-term mortality. Newer agents including tissue plasminogen activators such as alteplase, reteplase, tenecteplase were developed subsequently. In the present era, thrombolytic therapy and primary percutaneous coronary intervention has revolutionized the way patients with acute myocardial infarction are managed resulting in significant reduction in cardiovascular death. This article provides an overview of the various thrombolytic agents utilized in the management of patients with acute myocardial infarction.
冠心病是美国的单一主要死亡原因。几乎一个世纪前就已经确定冠状动脉阻塞是心肌梗死的原因。经过一系列的研究，发现链激酶并证明其对治疗急性心肌梗死患者具有益处，可以降低短期和长期死亡率。随后开发了新型药物，包括组织型纤溶酶原激活物如阿替普酶、瑞替普酶、替奈普酶。在当前时代，溶栓治疗和直接经皮冠状动脉介入治疗改变了急性心肌梗死患者的管理方式，显著降低了心血管死亡。本文概述了用于治疗急性心肌梗死患者的各种溶栓药物。
